Skip to main content

Table 2 Hazard ratios (HRs) and 95% confidence intervals for the incidence of cardiovascular disease and all-cause mortality during follow up according to the presence and type of diabetes mellitus

From: Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study

 

Individuals without diabetes

Individuals with type 2 diabetes

Individuals with type 1 diabetes

n = 18,500,151

n = 1,913,503

n = 9,397

Myocardial infarction

 Events (n)

83,712

32,666

271

 Follow-up duration (person-years)

84,157,841.27

9,193,771.11

44,306.51

 Incidence rate (per 100,000 person-years)

99.470

355.306

611.648

 Model 1

1 (Ref.)

1.869 (1.845–1.894)

3.321 (2.948–3.741)

–

1 (Ref.)

1.771 (1.571–1.996)

 Model 2

1 (Ref.)

1.601 (1.580–1.623)

2.844 (2.524–3.204)

–

1 (Ref.)

1.751 (1.554–1.974)

 Model 2-1

1 (Ref.)

1.279 (1.262–1.296)

2.183 (1.938–2.459)

–

1 (Ref.)

1.705 (1.513–1.922)

 Model 3

1 (Ref.)

1.562 (1.540–1.583)

2.739 (2.430–3.086)

–

1 (Ref.)

1.723 (1.529–1.942)

 Model 4

1 (Ref.)

1.418 (1.395–1.442)

2.411 (2.138–2.718)

–

1 (Ref.)

1.679 (1.490–1.893)

Hospitalization for HF

 Events (n)

89,173

36,448

376

 Follow-up duration (person-years)

84,188,450.19

9,203,077.54

44,238.57

 Incidence rate (per 100,000 person-years)

105.921

396.041

849.937

 Model 1

1 (Ref.)

1.753 (1.731–1.774)

3.955 (3.575–4.376)

–

1 (Ref.)

2.241 (2.025–2.480)

 Model 2

1 (Ref.)

1.606 (1.586–1.626)

3.604 (3.257–3.988)

–

1 (Ref.)

2.216 (2.002–2.453)

 Model 2-1

1 (Ref.)

1.463 (1.445–1.482)

3.233 (2.921–3.577)

–

1 (Ref.)

2.195 (1.983–2.429)

 Model 3

1 (Ref.)

1.578 (1.558–1.599)

3.390 (3.063–3.752)

–

1 (Ref.)

2.120 (1.915–2.348)

 Model 4

1 (Ref.)

1.417 (1.395–1.440)

3.024 (2.730–3.350)

–

1 (Ref.)

2.105 (1.901–2.330)

Atrial fibrillation

 Events (n)

105,562

29,743

227

 Follow-up duration (person-years)

84,127,796.33

9,204,929.38

44,425.71

 Incidence rate (per 100,000 person-years)

125.478

323.120

510.965

 Model 1

1 (Ref.)

1.268 (1.251–1.284)

2.073 (1.820–2.361)

–

1 (Ref.)

1.630 (1.430–1.857)

 Model 2

1 (Ref.)

1.147 (1.132–1.162)

1.885 (1.655–2.147)

–

1 (Ref.)

1.636 (1.436–1.864)

 Model 2-1

1 (Ref.)

1.046 (1.032–1.060)

1.694 (1.487–1.929)

–

1 (Ref.)

1.627 (1.427–1.853)

 Model 3

1 (Ref.)

1.147 (1.131–1.162)

1.829 (1.605–2.084)

–

1 (Ref.)

1.587 (1.392–1.808)

 Model 4

1 (Ref.)

1.085 (1.067–1.103)

1.748 (1.534–1.993)

–

1 (Ref.)

1.608 (1.411–1.833)

All-cause mortality

 Events (n)

249,622

94,018

876

 Follow-up duration (person-years)

84,326,798.16

9,261,598.81

44,788.78

 Incidence rate (per 100,000 person-years)

296.020

1015.140

1955.850

 Model 1

1 (Ref.)

1.569 (1.557–1.581)

3.145 (2.944–3.360)

–

1 (Ref.)

1.990 (1.862–2.127)

 Model 2

1 (Ref.)

1.685 (1.672–1.698)

3.345 (3.131–3.574)

–

1 (Ref.)

1.961 (1.835–2.096)

 Model 2-1

1 (Ref.)

1.885 (1.870–1.899)

3.801 (3.557–4.062)

–

1 (Ref.)

2.002 (1.873–2.139)

 Model 3

1 (Ref.)

1.635 (1.622–1.648)

3.120 (2.919–3.334)

–

1 (Ref.)

1.893 (1.771–2.024)

 Model 4

1 (Ref.)

1.510 (1.495–1.525)

2.874 (2.689–3.073)

–

1 (Ref.)

1.884 (1.762–2.013)

  1. Model 1: adjusted for age and sex
  2. Model 2: adjusted for model 1 + smoking history, alcohol history, regular exercise, monthly income, body mass index, hypertension, and dyslipidemia
  3. Model 2-1: adjusted for model 1 + smoking history, alcohol history, regular exercise, monthly income, body mass index, hypertension, and statin use. Statin use was defined as the prescription of statins for at least 6 months from baseline to the end of the follow-up
  4. Model 3: adjusted for model 1 + smoking history, alcohol history, regular exercise, monthly income, metabolic syndrome, and end-stage renal disease
  5. Model 4: adjusted for model 2 + fasting plasma glucose
  6. HF heart failure. 
  7. Statistically significant values among the hazard ratios (95% confidence intervals) were given in talic